Clovis Oncology, Inc.
CLVSNext catalyst
Copanlisib
Metastatic Castration-resistant Prostate Cancer
Get an email about CLVS's next catalysts
Track Clovis Oncology (CLVS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
Copanlisib Phase 2 Est. Readout
Estimated primary completion for Copanlisib trial (NCT04253262) in Metastatic Castration-resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceRucaparib Phase 2 Est. Readout
Estimated primary completion for Rucaparib trial (NCT04253262) in Metastatic Castration-resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceTrastuzumab and Pertuzumab (combination treatment) Phase 2 Est. Readout (DRUP)
Estimated primary completion for Trastuzumab and Pertuzumab (combination treatment) trial (NCT02925234) in Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
rucaparib
Metastatic Breast Cancer
Copanlisib
Metastatic Castration-resistant Prostate Cancer
Dostarlimab and Niraparib
Mesothelioma, Malignant
Dacomitinib
Cancer
Lorlatinib
Cancer
Selpercatinib
Cancer
Erdafitinib
Cancer
Vemurafenib and Cobimetinib (combination treatment)
Cancer
Regorafinib
Cancer
Trastuzumab and Pertuzumab (combination treatment)
Cancer
CO-1.01
Metastatic Pancreatic Adenocarcinoma
Dabrafenib and trametinib
Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rucaparib | Phase 3 | Metastatic Breast Cancer | - | - |
Copanlisib | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Dostarlimab and Niraparib | Phase 2 | Mesothelioma, Malignant | - | - |
Dacomitinib | Phase 2 | Cancer | - | - |
Lorlatinib | Phase 2 | Cancer | - | - |
Selpercatinib | Phase 2 | Cancer | - | - |
Erdafitinib | Phase 2 | Cancer | - | - |
Vemurafenib and Cobimetinib (combination treatment) | Phase 2 | Cancer | - | - |
Regorafinib | Phase 2 | Cancer | - | - |
Trastuzumab and Pertuzumab (combination treatment) | Phase 2 | Cancer | - | - |
CO-1.01 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Dabrafenib and trametinib | Phase 2 | Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Clovis Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Clovis Oncology, Inc.'s (CLVS) pipeline across Phase 3, Phase 2. Its lead program is rucaparib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Clovis Oncology, Inc.'s next FDA catalyst?→
Clovis Oncology, Inc.'s (CLVS) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLVS biotech catalysts?→
Add CLVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Clovis Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.